24 May 2013
Keywords: Santaris Pharma. Isis Pharma, US patents, Antisense molecules
Article | 30 November 2011
Denmark-based RNA-targeted therapies developer Santaris Pharma A/S says that it has won two significant patent re-examination cases brought by ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
29 November 2011
1 December 2011
23 May 2013
© 2013 thepharmaletter.com